Пользователь:
АНОНИМ
|
|
|
Изделия
Прайсы
Организации
Спрос
Выставки
Пресса
Объявления
Книги
ГосЗакупки
Персоналии
Исследования
Рубрикатор ::
Медицина/ Фармакология :: Медицинские услуги - общее ::
Russian pharmaceutical market 2010
Телефон для консультаций: +7(985)920-61-98 (телефон офиса в Москве), 8(800)55-189-55 (бесплатный телефон по РФ) Вы можете заказать данный отчёт в режиме on-line прямо сейчас, заполнив небольшую форму регистрации. Заказ отчёта не обязывает к его покупке. После получения заказа на отчёт с Вами свяжется наш менеджер, который:
Поля, отмеченные звёздочкой, обязательны для заполнения. Полное описание отчёта In 2010, the state played a leading role on the market: the number of legislative initiatives was unprecedented. This makes the market more open and ordered. In 2010, the financial indicators of pharmaceutical market were affected both by the consequence of the crisis, and by government regulation. In 2010, the pharmaceutical market volume has amounted to 667 billion rubles(including VAT) in end user prices, which is only 6% higher than that in 2009. The Russian pharmaceutical market is import oriented. 78% of drugs in money terms consumed by the population, are produced abroad. Therefore, the ranking of manufacturers is predominantly occupied by foreign companies: SANOFI-AVENTIS, NOVARTIS. The second line is occupied by PHARMSTANDART - the only domestic manufacturer in the TOP-20 of leading players in the Russian pharmaceutical market. The major playersin the commodity distribution network on the pharmaceutical market are the distributors. This is due to the geographic specifics of the country - its large area. According to the results of 2010, the leaders in the distribution segment are CV Protek and SIA International. Their joint market share amounts to 37%. Specialized distributors (R-PHARM, Pulse) are growing rapidly. Pharmacy segment of the Russian market is represented by the huge number of participants. The largest networks are “36.6”, “Rigla”, “Implozia” - their total share reaches 7%. In 2010, the pharmacy networks divided into 2 groups: those who continued business optimization (36.6, Pharmacor, Doctor Stoletov), and those who made investmentsin expanding the quantitative composition of the network (Rigla, A5, Melodiya Zdorovya). In 2010, commercial segment of the Russian market shows low growth rate (+6%). Due to strict governmental control over vital drug inflation, the market has lost one of its main drivers: increase in drug prices in the commercial segment was minimal +1%, whereas in 30% of products (vital drugs) the prices have fallen by 4%. Growth of consumption in kind by + 3% may be considered a positive factor. In 2010 the sales volume in commercial segment amounted to about 406 billion rubles (13.4 billion dollars). This is only by 6% more than in 2009. Подробное оглавление/содержание отчёта 1. Pharmaceutical market volume in Russia 2. Commercial segment of RTU drugs 3. Drug Reimbursement Program (DLO) 4. Sales value in the segment of health care institutions (HCI) 5. Nutritional Supplements 6. Beauty products 7. Drug Import 8. Pharmacy Networks 9. Distribution Segment of the Pharmaceutical Market 10. Manufacturing Перечень приложений
Исследования по теме
Возник вопрос по содержанию отчёта? Задайте его! Персональный менеджер свяжется с Вами и поможет решить любую задачу.
Актуальные исследования и бизнес-планы
|
||||||||||||||||||||||||||||||||||||
|
Поиск организаций Поиск изделий | ||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Обмен ссылками |
|